Priming of immune responses to hepatitis B surface antigen in young mice immunized in the presence of maternally derived antibodies

FEMS Immunology and Medical Microbiology

Volumn 30, Issue 3, 2001, Pages 241-247

  Weeratna, Risini D ^a   Brazolot Millan, Cynthia L ^b   McCluskie, Michael J ^a   Siegrist, Claire Anne ^c   Davis, Heather L ^a,b,d,e  

^a Coley Pharmaceutical Canada ^*  (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF GENEVA   (Switzerland)

^d Faculty of Health Sciences   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

Author keywords

CpG ODN; DNA vaccine; Immunization; Maternally transferred antibody

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; MATERNAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CPG ISLAND; CYTOTOXIC T LYMPHOCYTE; HEPATITIS B VIRUS; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NEWBORN; NONHUMAN; PLASMID; PRIORITY JOURNAL; SEROCONVERSION;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANIMALS, NEWBORN; DNA; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNIZATION; MALE; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 0035037517     PISSN: 09288244     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-8244(01)00231-0     Document Type: Article

References (34)

1. Standardization of smallpox vaccines and the eradication programme - A WHO perspective
2. Determinants of infant responses to vaccines in presence of maternal antibodies
3. DNA immunization of neonates induces immunity despite the presence of maternal antibody
4. Neonatal DNA immunization with a plasmid encoding an internal viral protein is effective in the presence of maternal antibodies and protects against subsequent viral challenge
5. Immunization of neonates with DNA encoding a bovine herpesvirus glycoprotein is effective in the presence of maternal antibodies
6. Genetic immunization of seronegative one-day-old piglets against pseudorabies induces neutralizing antibodies but not protection and is ineffective in piglets from immune dams
7. Effect of passive immunization or maternally transferred immunity on the antibody response to a genetic vaccine to rabies virus
8. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response
9. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients
10. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine
11. CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis
12. Synthetic oligodeoxynucleotide containing CpG motif induces an anti-polysaccharide type 1-like immune response after immunization of mice with Haemophilus influenzae type b conjugate vaccine
13. CpG DNA as mucosal adjuvant
14. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major
15. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-γ-dependent mechanisms
16. Immunostimulatory CpG motifs trigger a T helper-1 immune response to human immunodeficiency virus type-1 (HIV-1) gp 160 envelope proteins
17. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice
18. CpG DNA: A novel adjuvant for systemic and mucosal immunization with influenza virus
19. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen
20. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs
21. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice
22. Effective priming of neonates born to immune dams against the immunogenic pseudorabies virus glycoprotein gD by replication-incompetent adenovirus-mediated gene transfer at birth
23. Orally administered microencapsulated reovirus can bypass suckled, neutralizing maternal antibody that inhibits active immunization of neonates
24. Vaccine strategies to overcome maternal antibody mediated inhibition of measles vaccine
25. Vaccination in the neonatal period and early infancy
26. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo
27. CpG ODN is safe and highly effective in humans as adjuvant to HBV vaccine: Preliminary results of Phase I trial with CpG ODN 7909
28. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans
29. CpG DNA induces stronger immune responses with less toxicity than other adjuvants
30. CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming
31. Induction of protective CTL responses in newborn mice by a murine retrovirus
32. - T cell responses: The alternative approaches
33. Influence of maternal antibodies on vaccine responses: Inhibition of antibody but not T cell responses allows successful early prime-boost strategies in mice
34. Viral clearance without destruction of infected cells during acute HBV infection